Bisphosphonates and metabolic bone disease in the ICU

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 12, Issue 2, 2009, Pages 190-195

  Hollander, Jason M ^a,c   Mechanick, Jeffrey I ^b  

^a Princeton Endocrinology   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Bisphosphonate; Critical illness; ICU; Metabolic bone disease; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; ERGOCALCIFEROL; IBANDRONIC ACID; INTERLEUKIN 1; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ARTHRALGIA; BONE DISEASE; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; CRITICAL ILLNESS; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DRUG CLEARANCE; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; ENDOCRINE DISEASE; FEMUR FRACTURE; FEVER; FLU LIKE SYNDROME; FRAGILITY FRACTURE; FROZEN BONE; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; IMMOBILIZATION; INTENSIVE CARE UNIT; JAW OSTEONECROSIS; KIDNEY FAILURE; METABOLIC BONE DISEASE; MYALGIA; NEPHROTOXICITY; OSTEOLYSIS; PARESTHESIA; PATHOGENESIS; PROPHYLAXIS; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; TETANY; TREATMENT RESPONSE; VITAMIN D DEFICIENCY;

BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BONE RESORPTION; CRITICAL ILLNESS; DIPHOSPHONATES; HUMANS; INTENSIVE CARE UNITS;

EID: 61949467564     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e328321cda6     Document Type: Review

References (47)

1. Shapses SA, Weissman C, Seibel MJ, Chowdhury HA. Urinary pyridinium cross-link excretion is increased in critically ill surgical patients. Crit Care Med 1997; 25:85-90.
2. Smith LM, Cuthbertson B, Harvie J, et al. Increased bone resorption in the critically ill: association with sepsis and increased nitric oxide production. Crit Care Med 2002; 30:837-840.
3. Van den Berghe G, Van Roosbroeck, Wouters PJ, et al. Bone turnover in prolonged critical illness: effect of vitamin D. J Clin Endocrinol Metab 2003; 88:4623-4632.
4. Chapurlat RD, Garnero P, Breart G, et al. Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone 2000; 27:283-286.
5. 5 Melton U, Khosla S, Atkinson EJ, et al. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997; 12:1083-1091.
6. Komemushi A, Tanigawa N, Kariya S, et al. Biochemical markers of bone turnover in percutaneous vertebroplasty for osteoporotic compression fracture. Cardiovasc Intervent Radiol 2008; 31:332-335. This study demonstrates the value of biochemical bone markers in predicting fracture.
7. Nierman DM, Mechanick JI. Bone hyperresorption is prevalent in chronically critically ill patients. Chest 1998; 114:1122-1128.
8. Boyce BF, Li P, Yao Z, et al. TNF-alpha and pathologic bone resorption. Keio J Med 2005; 54:127-131.
9. Ding C, Parameswaran V, Udayan R, et al. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab 2008; 93:1952-1958. This study demonstrates a significant correlation between the inflammatory cytokines TNF-ct and IL-6 and bone loss as measured by bone mineral density.
10. Ruml LA, Dubois SK, Roberts ML, Pak CY. Prevention of hypercalciuria and stone-forming propensity during prolonged bedrest by alendronate. J Bone Miner Res 1995; 10:655-662.
11. Hollander JM, Mechanick JI. Nutrition support and the chronic critical illness syndrome. Nutr Clin Pract 2006; 21:587-604.
12. Vanhorebeek I, Van den Berghe G. The neuroendocrine response to critical illness is a dynamic process. Crit Care Clin 2006; 22:1-15.
13. Bornstein SR, Chrousos GP. Adrenocorticotropin (ACTH) and non-ACTH-mediated regulation of the adrenal cortex: neural and immune inputs. J Clin Endcorinol Metab 1999; 84:1729-1736.
14. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 25:97-106.
15. Russell RG, Rogers MJ, Frith JC, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 1999; 14:53-65.
16. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296:235-242.
17. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356:1809-1822.
18. Mok CC, Tong KH, To CH, et al. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. Osteoporos Int 2008; 19:357-364. This study demonstrates that bisphosphonates reduce bone loss in patients on high dose glucocorticoid therapy (0.5mg/kg/day).
19. Gngg AP, Shuttleworth P, Reynolds J, et al. Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2006; 91:3835-3843.
20. Gilchrist NL, Frampton CM, Acland RH, et al. Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2007; 92:1385-1390. This study clearly demonstrates that bisphosphonate therapy is effective at reducing bone loss following an acute spinal cord injury.
21. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Zo-FAST Study results. Cancer 2008; 112:1001-1010. Bone loss can be quite severe following the initiation of an aromatase inhibitor. This study demonstrates that i.v. zoledronic acid can significantly blunt bone loss caused by aromatase inhibitor treatment.
22. Michaelson MD, Kaufamn DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonis-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25:1038-1042.
23. Kawada K, Minami H, Okabe K, et al. A multicenter and open label clinical trial of Zoledronic acid 4 mg in patients with hypercalcemia of malignancy. Jpn J Clin Oncol 2005; 35:28-33.
24. Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008; 3:228-236. This retrospective analysis of patients with nonsmall cell lung cancer demonstrates increased survival in patients treated with zoledronic acid, particularly in those with highest levels of NTx.
25. Facchini G, Caraglia M, Santini D, et al. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events. J Exp Clin Cancer Res 2007; 26:307-312.
26. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomized, placebo controlled phase III studies. Br J Cancer 2004; 90:1133-1137.
27. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357:1799-1809.
28. Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008; 35:488-497.
29. This study demonstrates that i.v. ibandronate is more effective at increasing bone mineral density than orally administered ibandronate.
30. Merlotti D, Gennari L, Martini G, et al. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone. J Bone Miner Res 2007; 22:1510-1517.
31. Hewitt RE, Lissina A, Green AE, et al. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 2005; 139:101-111.
32. Munier A, Gras V, Andrejak M, et al. Zoledronic acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 2005; 39:1194-71197.
33. Smetana S, Michlin A, Resenman E, et al. Pamidronate-induced nephrotoxic tubular necrosis: a case report. Clin Nephrol 2004; 61:63-67.
34. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008; 74:1385-1393.
35. Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008; 168:826-831. This population-based case-control study found that a history of using alendronate increased ones risk of incident atrial fibrillation.
36. King AE, Umland EM. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacoptherapy 2008; 28: 667-677. This extensive review of the literature found that 94% of reported cases of osteonecrosis of the jaw occurred in individuals receiving treatment for cancer.
37. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008; 93:2948-2952. This case series describes three patients on long-term bisphosphonates who develop atypical skeletal fragility.
38. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of aledronate therapy. J Clin Endocrinol Metab 2005; 90:1294-1301.
39. Nierman DM, Mechanick JI. Biochemical response to treatment of bone hyperresorption in chronically critically ill patients. Chest 2000; 118:761-766.
40. Klein GL, Wimalawansa SJ, Kulkarni G, et al. The efficacy of acute administration of pamidronate on the conservation of bone mass following severe burn injury in children: a double-blind, randomized, controlled study. Osteoporos Int 2005; 16:631-635.
41. Przkora R, Herndon DN, Sherrard DJ, et al. Pamidronate preserves bone mass for at least 2 years following acute administration for pediatric burn injury. Bone 2007; 66:164-166.
42. Grant W, Holick M. Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev 2005; 10:94-111.
43. Zazzo FJ, Troche G, Ruel P, Maintenant J. High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorous therapy in myocardial function. Intensive Care Med 1995; 21:826-831.
44. Rimaniol JM, Authier FJ, Chariot P. Muscle weakness in intensive care patients: initial manifestation of vitamin D deficiency. Intensive Care Med 1994; 20:591-592.
45. Teitelbaum SL, Hruska KA. Renal osteodystrophy. N Engl J Med 1995; 333:166-174.
46. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (4Suppl3):S1-S201.
47. Bergner R, Dill K, Boerner D, Uppenkamp M. Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. Nephrol Dial Transplant 2002; 17:1281-1285.